Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Melanoma 32Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Ovarian Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 4Hematologic Neoplasms 4Solid Tumors 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Solid Tumor 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Histologic Type 2Leukemia, Myelomonocytic, Chronic 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × cobimetinib × Clear all
NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
57 enrolled 13 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
86 enrolled 16 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡